Fri, Aug 26, 2016
Biocon informed that EMA has accepted for review of Mylan's market authorization application (MAA) for a proposed biosimilar Trastuzumab, which is used to treat certain breast and gastric cancer.
More >
Fri, Jun 03, 2016
The company's stock soared 8.54% to settle at Rs 518.35 on the Bombay Stock Exchange (BSE).
By accepting cookies, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.
